Is Supernus Pharmaceuticals Stock a Good Investment?
Supernus Pharmaceuticals Investment Advice | SUPN |
- Examine Supernus Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Supernus Pharmaceuticals' leadership team and their track record. Good management can help Supernus Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Supernus Pharmaceuticals' business and its evolving consumer preferences.
- Compare Supernus Pharmaceuticals' performance and market position to its competitors. Analyze how Supernus Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Supernus Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Supernus Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Supernus Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Supernus Pharmaceuticals is a good investment.
Sell | Buy |
Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Supernus Pharmaceuticals Stock
Researching Supernus Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 95.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.76. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Supernus Pharmaceuticals has Price/Earnings To Growth (PEG) ratio of 1.47. The entity had not issued any dividends in recent years.
To determine if Supernus Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Supernus Pharmaceuticals' research are outlined below:
| Supernus Pharmaceuticals generated a negative expected return over the last 90 days | |
| Supernus Pharmaceuticals currently holds 34.27 M in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Supernus Pharmaceuticals has a current ratio of 0.83, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Supernus Pharmaceuticals' use of debt, we should always consider it together with its cash and equity. | |
| Over 95.0% of Supernus Pharmaceuticals shares are owned by institutional investors |
Supernus Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Supernus Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Supernus Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Supernus Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.84 B.Supernus Pharmaceuticals' profitablity analysis
The company has Profit Margin (PM) of 0.11 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.11 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.11.Determining Supernus Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Supernus Pharmaceuticals is a good buy. For example, gross profit margin measures Supernus Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Supernus Pharmaceuticals' profitability and make more informed investment decisions.
Basic technical analysis of Supernus Stock
As of the 26th of March, Supernus Pharmaceuticals has the Coefficient Of Variation of (1,893), risk adjusted performance of (0.04), and Variance of 7.21. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Supernus Pharmaceuticals, as well as the relationship between them.Supernus Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Supernus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Supernus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Supernus Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Supernus Pharmaceuticals' Outstanding Corporate Bonds
Supernus Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Supernus Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Supernus bonds can be classified according to their maturity, which is the date when Supernus Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Supernus Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Supernus Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.28) | |||
| Mean Deviation | 1.59 | |||
| Coefficient Of Variation | (1,893) | |||
| Standard Deviation | 2.68 | |||
| Variance | 7.21 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | (0.14) | |||
| Treynor Ratio | (0.29) | |||
| Maximum Drawdown | 22.74 | |||
| Value At Risk | (2.63) | |||
| Potential Upside | 2.48 | |||
| Skewness | (2.99) | |||
| Kurtosis | 18.76 |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.28) | |||
| Mean Deviation | 1.59 | |||
| Coefficient Of Variation | (1,893) | |||
| Standard Deviation | 2.68 | |||
| Variance | 7.21 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | (0.14) | |||
| Treynor Ratio | (0.29) | |||
| Maximum Drawdown | 22.74 | |||
| Value At Risk | (2.63) | |||
| Potential Upside | 2.48 | |||
| Skewness | (2.99) | |||
| Kurtosis | 18.76 |
Consider Supernus Pharmaceuticals' intraday indicators
Supernus Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Supernus Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 11436.9 | |||
| Daily Balance Of Power | (0.52) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 32.81 | |||
| Day Typical Price | 32.65 | |||
| Price Action Indicator | (0.84) | |||
| Period Momentum Indicator | (0.72) | |||
| Relative Strength Index | 34.19 |
Supernus Stock media impact
Far too much social signal, news, headlines, and media speculation about Supernus Pharmaceuticals that are available to investors today. That information is available publicly through Supernus media outlets and privately through word of mouth or via Supernus internal channels. However, regardless of the origin, that massive amount of Supernus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Supernus Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Supernus Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Supernus Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Supernus Pharmaceuticals alpha.
Supernus Pharmaceuticals Corporate Management
| Padmanabh Bhatt | Chief Scientific Officer and Sr. VP of Intellectual Property | Profile | |
| Tami Martin | VP Affairs | Profile | |
| Jeff Bozick | Senior Chain | Profile | |
| Kevin Esq | Compliance Officer | Profile | |
| Taylor Raiford | Senior Sales | Profile | |
| Bryan Roecklein | Senior Development | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Supernus Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.